Tata Medical and Diagnostics, the healthcare unit of India’s Tata Group has launched a Covid-19 test kit that will process results more easily and faster than the RT-PCR method.
TataMD CHECK, as the product is called, has received approvals from Indian Council of Medical Research and Drug Controller General of India (DCGI). It will be available through diagnostic centres and hospitals across India shortly.
“We are setting a new standard in Covid-19 testing with the launch of TataMD’s CHECK, powered by FELUDA and made in India through our partnership with Institute of Council of Scientific and Industrial Research’s constituent lab, Institute of Genomics and Integrative Biology (CSIR-IGIB),” Tata Group said in a Tweet.
This is said to be the world’s first CRISPR Cas-9 based Covid-19 testing. The paper-based sample test delivers results in 45-50 minutes in a laboratory.
Tata Medical and Diagnostics will begin manufacturing one million kits a month at its plant in the southern city of Chennai.
The Tata Group has stated that the test is ‘traceable, transparent and trusted with digital quality control and Artificial Intelligence-based result reporting tool’.
